Sanofi: €1.3 billion for insulin production in Germany
The project aims to "ensure long-term supply of essential insulin for people living with diabetes while strengthening the resilience of the European supply chain," explained Sanofi. Support for this came from the federal government and the Hessian state government. Sanofi Germany CEO Heidrun Irschik-Hadjieff spoke of a "significant signal for the biopharmaceutical industry."
In November 2023, US pharmaceutical giant Eli Lilly had already announced an investment of 2.3 billion euros in Germany to expand its production of diabetes medications, some of which are also used for weight loss. Danish company Novo Nordisk, the world's leading insulin manufacturer, is expanding its French production site in Chartres with an investment of 2.1 billion. The current Sanofi site in Höchst covers the entire insulin production chain, from active ingredient (API) manufacturing to syringe production and global distribution.
Sanofi, as mentioned earlier, is the company that spearheaded the project aimed at ensuring a long-term supply of essential insulin for diabetes patients while enhancing the resilience of the European supply chain. The expansion plans of Sanofi at its site in Höchst include the entire insulin production chain, encompassing the manufacturing of active ingredients, syringe production, and global distribution.
